Jcr Pharmaceuticals Co., Ltd. · TSE:4552

Jcr Pharmaceuticals — H1 FY2023 Earnings Presentation

16 slides from Jcr Pharmaceuticals's earnings presentation, Oct 25, 2023

  1. Slide 1: Appendix to the Consolidated Financial Summary FY2023 First-Half

    Appendix to the Consolidated Financial Summary FY2023 First-Half October 25, 2023 JCR Pharmaceuticals Co., Ltd. Copyright © 2023 JCR Pharmaceuticals Co., Ltd. All rights reserved.

  2. Slide 2: Contents

    Contents Consolidated Financial Results 2 Consolidated Financial Results - Supplemental Information 3 Breakdown of Net Sales (Consolidated) 4 Breakdown of Net Sales (Consolidated) - Supplemental Information 5 Financial Status (Consolidated) 6 Financial Status (Consolidated) - Supplemental Informatio

  3. Slide 3: Consolidated Financial Results

    Consolidated Financial Results （Unit: million yen） FY2022 FY2023 Consolidated Year-on-year Full-year ◆ Operating income 6,898 million yen Full-year 1H 1H Progress results results results Difference Ratio forecast (Revised) rate Year-on-year: +6,153 million yen Net sales 34,343 15,581 24,272 +8,691 ＋

  4. Slide 4: Consolidated Financial Results - Supplemental Information

    Consolidated Financial Results - Supplemental Information Supplemental Information on the Consolidated Financial Results • Sales and profits increased significantly year on year, primarily due to increases in product sales and license revenue. • The increase in cost of sales was due to higher produc

  5. Slide 5: Breakdown of Net Sales (Consolidated)

    Breakdown of Net Sales (Consolidated) （Unit: million yen） FY2022 FY2023 ◆Net sales 24,272 million yen Consolidated Year-on-year Full-year Full-year 1H 1H forecast Progress Year-on-year: +8,691 million yen results results results (Revised) rate Difference Ratio GROWJECT® 12,261 6,083 8,746 +2,663 +43

  6. Slide 6: Breakdown of Net Sales (Consolidated) - Supplemental Information

    Breakdown of Net Sales (Consolidated) - Supplemental Information Supplemental Information on the Breakdown of Net Sales • Significant sales growth of GROWJECT®, steady market penetration of IZCARGO®, and solid sales of TEMCELL® contributed to the increase in net sales. • Sales of treatment for renal

  7. Slide 7: Financial Status (Consolidated)

    Financial Status (Consolidated) （Unit: million yen） Change Change End-Mar. End-Sep. End-Mar. End-Sep. ・ Main ・ Main 2023 2023 2023 2023 Increase/decrease Increase/decrease Total +10,095 Total (3,766) ・ Income taxes Current • Cash and deposits 35,762 31,995 payable +2,503 liabilities +2,689 ・ Short-t

  8. Slide 8: Financial Status (Consolidated) - Supplemental Information

    Financial Status (Consolidated) - Supplemental Information Supplemental Information on Financial Status • The increase in accounts receivable - trade and contract assets was due to the recording of license revenue and significant sales growth of GROWJECT®. • The decrease in short-term borrowings and

  9. Slide 9: Cash Flows (Consolidated)

    Cash Flows (Consolidated) (Unit: million yen) FY2022 1H FY2023 1H Year-on-year Operating Activities 営業活動によるCF Profit before income taxes 1,560 7,120 ＋5,559 Investing Activities 投資活動によるCF Depreciation 953 1,335 ＋381 Decrease (increase) in trade receivables and 財務活動によるCF Financing Activities 6,497 (8,

  10. Slide 10: Net Sales Trends by Product

    Net Sales Trends by Product 19,500 Recombinant human growth hormone product Recombinant therapeutic enzyme for mucopolysaccharidosis II (MPS II) （Unit: million yen） GROWJECT® IZCARGO® I.V. infusion 10mg 13,256 12,945 From April 24, 2023: Co-promotion with Sumitomo Pharma Co., Ltd. 12,261 5,500 8,746

  11. Slide 11: Composition of Net Sales by Item

    Composition of Net Sales by Item 3% ● GROWJECT® 8,746 million yen ● IZCARGO® 2,581 million yen ● TEMCELL® HS Inj. 29% 36% 1,901 million yen Total net sales ● Epoetin Alfa BS Inj. [JCR] 24,272 1,046 million yen million yen ● Darbepoetin Alfa BS Inj. [JCR] 1,628 million yen ● Agalsidase Beta BS I.V. I

  12. Slide 12: Trends in Sales Breakdown (Consolidated)

    Trends in Sales Breakdown (Consolidated) 23,898 (Unit: million yen) 0 8,046 664 16,721 18,416 14,834 51 7,112 AZD1222原液 AZD1222 stock solution 11 6,329 0 その他 404 53 Other 契約金from contractual payment Income 7,557 51 10,744 Agalsidase BetaベータBS BS 590 アガルシダーゼ 5,536 7,672 TEMCELL 1,931 1,901 テムセル 3,014

  13. Slide 13: Net Sales Trends (Excluding AZD1222 Stock Solution)

    Net Sales Trends (Excluding AZD1222 Stock Solution) 製商品*売上高 Products* sales 契約金 Income from contractual payment （Unit: million yen） * Products: GROWJECT, IZCARGO, treatment for renal anemia, TEMCELL, Agalsidase Beta BS I.V. Infusion [JCR], others 8,100 10,571 6,546 2,050 6,406 7,112 37,300 26,134 25

  14. Slide 14: Trends in Composition Ratio of Cost/Expense

    Trends in Composition Ratio of Cost/Expense (Unit: million yen) 営業利益profit研究開発費 ■Operating ■ R&D expenses 販売費・一般管理費■ SG&A 売上原価■ Cost of sales 20.5% 26.0% 25.9% 24.2% 31.9% 10,461 31.0% 7,812 8,886 5,881 7,901 4,836 26.5% 24.5% 28.7% 13,511 34.0% 5,957 8,643 30.8% 11,678 37.1% 7,638 14.0% 5,782 7,175

  15. Slide 15: Correlation between R&D Expenses (before Deducting) and Main R&D Pipeline

    Correlation between R&D Expenses (before Deducting) and Main R&D Pipeline Process development/ 11,700 （Unit: million yen） Non-clinical 9,480 Clinical trial 7,671 6,582 5,856 Filed an application Approved 2020年3月期 FY2019 2021年3月期 FY2020 2022年3月期 FY2021 2023年3月期 FY2022 2024年3月期（予想） FY2023 (forecast) J

  16. Slide 16: Copyright © 2023 JCR Pharmaceuticals Co., Ltd. All rights reserved.

    Copyright © 2023 JCR Pharmaceuticals Co., Ltd. All rights reserved.

JCR Pharmaceuticals — H1 FY2023 Earnings Presentation on 6ix